Formulary Decisions
Search for the outcome of decisions made by the Formulary Committee
Adalimumab
Adalimumab
Routinely available
NICE (TA383 (SMC 300/06))
04/12/2024
Indication
Severe active ankylosing spondylitis
Therapeutic Area
Musculoskeletal and joint diseases
Status Description
Routinely available in line with national guidance
Formulation
-
Comments
Refer to pathway or local board guidelines for preferred formulation
Link to Advice
Advice Published
01/02/2016